deamidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Over the following decade, numerous Half-Life games were canceled, including Episode Three, a version of Half-Life 3, Borealis, a Source 2 VR spin-off, and games developed by Junction Point Studios and Arkane Studios. In 2020, after years of speculation, Valve released Half-Life: Alyx, which was developed exclusively for virtual reality headsets. It is a prequel set five years before Half-Life 2, where players control Freeman's eventual ally Alyx Vance in her quest to rescue her father from Combine forces and uncover their mysterious "super-weapon". The Half-Life series is recognized by critics and industry experts for producing some of the most influential first-person shooter games for the genre, both of which have been highlighted for their advancements towards immersive and varied gameplay, level design, storytelling, visuals and sound. Half-Life and Half-Life 2, as well as Portal and Portal 2, have in particular been cited by numerous publications in being considered among the greatest video games ever made.
The first selective CCKB receptor antagonists were modified peptide molecules such as CI-988 and the more metabolically stable CI-1015, however these were disadvantaged by only being able to be administered by injection and rapid breakdown inside the body, which led to a short half-life and limited utility. Non-peptide CCKB receptor antagonists such as L-365,260, L-369,293, YF-476, RP-69758, LY-288,513, PD-145,942 and the CCKB receptor inverse agonist L-740,093 have since been developed, and while all of the drugs developed so far have suffered from limited bioavailability or other issues which have hindered their clinical development, research in this area continues. CCKA receptors are also expressed in the brain to some extent, and IQM-95333, an antagonist selective for this population of CCKA receptors, was also found to reduce anxiety in animal models. Conversely, inhibition of CCKB receptors in the gut produces similar inhibition of secretion of gastric acid and pepsinogen enzymes as is seen with inhibition of CCKA receptors, suggesting that while the CCKA and CCKB receptors comprise two structurally distinct families which bind different ligands and are primarily expressed in different tissues, they produce similar effects, and the distinction between their gastrointestinal and anxiolytic actions depends mainly on where they are expressed in the body.
=== Laurent's half-shade polarimeter === When plane-polarised light passes through some crystals, the velocity of left-polarized light is different from that of the right-polarized light, thus the crystals are said to have two refractive indices, i.e. double refracting. Construction: The polarimeter consists of a monochromatic source S which is placed at focal point of a convex lens L. Just after the convex lens there is a Nicol Prism P which acts as a polariser. H is a half shade device which divides the field of polarized light emerging out of the Nicol P into two halves, generally of unequal brightness. T is a glass tube in which an optically active solution is filled. The light, after passing through T, is allowed to fall on the analyzing Nicol A which can be rotated about the axis of the tube. The rotation of the analyzer can be measured with the help of a scale C. Working principle: To understand the need of a half-shade device, let us suppose that it is not present. The position of the analyzer is adjusted so that the field of view is dark when the tube is empty. The position of the analyzer is noted on the circular scale. Now the tube is filled with the optically active solution and it is set in its proper position. The optically active solution rotates the plane of polarization of the light emerging out of the polarizer P by some angle, so the light is transmitted by analyzer A and the field of view of the telescope becomes bright. Now the analyzer is rotated by a finite angle so that the field of view of the telescope again becomes dark.
=== DNA repair === RECQL4 has a crucial role in DNA end resection that is the initial step required for homologous recombination (HR)-dependent double-strand break repair. When RECQL4 is depleted, HR-mediated repair and 5' end resection are severely reduced in vivo. RECQL4 also appears to be necessary for other forms of DNA repair including non-homologous end joining, nucleotide excision repair and base excision repair. The association of deficient RECQL4-mediated DNA repair with accelerated aging is consistent with the DNA damage theory of aging.
Sources: en.wikipedia.org
Wittner (1962), historian on peace movements Peter Winn (1962), professor of history at Tufts University Richard Alba (1963), sociologist, professor at Graduate Center, CUNY David Berlinski (1963), mathematician, professor Eric Foner (1963), preeminent historian of Reconstruction, winner of the Pulitzer Prize for History and former president of American Historical Association David Orme-Johnson (1963), professor of psychology at the Maharishi University of Management Michael Klare (1963), professor of security studies at Hampshire College Victor Margolin (1963), professor of design history at the University of Illinois at Chicago Jonah Raskin (1963), writer, professor on counterculture Howard Spodek (1963), historian specializing in urban studies; professor at Temple University Robert J. Art (1964), professor of international relations at Brandeis University Richard P. Appelbaum (1964), professor of sociology at University of California, Santa Barbara Jonathan R. Cole (1964), sociologist and provost of Columbia University 1989–2003 Peter S. Donaldson (1964), professor of English literature at the Massachusetts Institute of Technology Richard Epstein (1964), libertarian law scholar Richard S. Kayne (1964), professor of linguistics at New York University Peter Kolchin (1964), professor at the University of Delaware and winner of the 1988 Bancroft Prize John H. Langbein (1964), Sterling Professor at Yale Law School Peter K.
=== Maintenance and surveillance === Ideally, wound dressings should be changed daily to promote a clean environment and allow for daily evaluation of wound progression. Highly exudative wounds and infected wounds should be monitored closely and may require more frequent dressing changes. Negative pressure wound dressings can be changed less frequently, every 2–3 days. Wound progression over time can be monitored with transparent sheet tracings or photographs, each of which produce reliable measurements of wound surface area.
=== Sector-focused developments include: === KEZAD Business District (announced June 2025), a 3 km² mixed-use development with commercial towers, F&B outlets and business support zones near the KEZAD Headquarters. Abu Dhabi Food Hub, designed for regional food trading, processing, and cold chain logistics Aquaculture and Related Industries Zone, a 1.1 km² area for aquaculture and associated industries. Al Ain AgTech Park, a 200-hectare agtech park with an annual production capacity of 39 kilotonnes. KEZAD Global Auto Hub, developed with AED 330 million investment for automotive parts, storage and assembly. Rahayel Automotive City, a 1.1 million m² complex dedicated to automative activities and services.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.